• Greater Twin Cities: 715.294.4371

  • Search

Services

Purchase Pregabalin (Lyrica) capsules online


How and where to order Lyrica (Pregabalin) 75 mg, 150 mg, 300 mg capsules or tablets online:

Shop 1: DFH PHARMACY - 10% discount coupon DFHDCC
Shop 2: MEDS DIRECT SHOP - 30% bonus pills for reorders
Prices: from $0.70 per pill
Forms: 75 mg, 150 mg, 300 mg capsules
Quantity: 30-240 pills
Type: Pregabalin brand, Lyrica generic
Payment: Visa, Mastercard, AmEx, Cryptocurrencies
Delivery: Standard airmail and trackable courier service
Shipping: Worldwide, including USA, UK, Europe, Canada, Australia

Indications and usage:

Lyrica (Pregabalin) is indicated for:

  • neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN)
  • nerve pain associated with spinal cord injury
  • adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older
  • certain other types of seizures and nerve pain in patients with epilepsy
  • fibromyalgia
  • chronic low back pain
  • generalized anxiety disorder, social anxiety disorder, other anxiety conditions
  • post-traumatic stress disorder
  • obsessive-compulsive disorder
  • alcohol withdrawal
  • restless leg syndrome
  • decreasing doses of opioids before surgery
  • migraine prevention


    Dosage and administration:

  • For adult indications, begin dosing at 150 mg/day.
  • Dosing recommendations:

    Indication Dosing Regimen Maximum Dose
    DPN Pain 3 divided doses per day 300 mg/day within 1 week
    PHN 2 or 3 divided doses per day 300 mg/day within 1 week, maximum dose of 600 mg/day
    Adjunctive Therapy for Partial-Onset Seizures in Pediatric and Adult Patients Weighing 30 kg or More 2 or 3 divided doses per day Maximum dose of 600 mg/day
    Adjunctive Therapy for Partial-Onset Seizures in Pediatric Patients Weighing Less than 30 kg 1 month to less than 4 years: 3 divided doses per day, 4 years and older: 2 or 3 divided doses per day 14 mg/kg/day
    Fibromyalgia 2 divided doses per day 300 mg/day within 1 week, maximum dose of 450 mg/day
    Neuropathic Pain Associated with
    Spinal Cord Injury    		 2 divided doses per day 300 mg/day within 1 week, maximum dose of 600 mg/day


  • Dose should be adjusted in adult patients with reduced renal function.


    Overdosage:

    Signs, symptoms and laboratory findings of acute overdosage in humans

    In the postmarketing experience, the most commonly reported adverse events observed with pregabalin when taken in overdose include reduced consciousness, depression/anxiety, confusional state, agitation, and restlessness. Seizures and heart block have also been reported. Deaths have been reported in the setting of lone Lyrica overdose and in combination with other CNS depressants.

    Treatment or management of overdose

    There is no specific antidote for overdose with pregabalin. If indicated, elimination of unabsorbed drug may be attempted by emesis or gastric lavage; observe usual precautions to maintain the airway. General supportive care of the patient is indicated including monitoring of vital signs and observation of the clinical status of the patient. Contact a Certified Poison Control Center for up-to-date information on the management of overdose with pregabalin.

    Lyrica can be removed by hemodialysis. Standard hemodialysis procedures result in significant clearance of pregabalin (approximately 50% in 4 hours).


    Dosage forms and strengths:

  • Lyrica (Pregabalin) capsules: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg.
  • Lyrica (Pregabalin) oral solution: 20 mg/mL.


    Contraindications:

    Known hypersensitivity to pregabalin or any of its components.


    Warnings and precautions:

  • Angioedema (e.g., swelling of the throat, head and neck) can occur, and may be associated with life-threatening respiratory compromise requiring emergency treatment. Discontinue Lyrica immediately in these cases.
  • Hypersensitivity reactions (e.g., hives, dyspnea, and wheezing) can occur. Discontinue pregabalin immediately in these patients.
  • Antiepileptic drugs, including Lyrica (Pregabalin), increase the risk of suicidal thoughts or behavior.
  • Respiratory depression: May occur with Lyrica, when used with concomitant CNS depressants or in the setting of underlying respiratory impairment. Monitor patients and adjust dosage as appropriate.
  • This medication may cause dizziness and somnolence and impair patients' ability to drive or operate machinery.
  • Increased seizure frequency or other adverse reactions may occur if pregabalin is rapidly discontinued. Withdraw Lyrica gradually over a minimum of 1 week.
  • This medicine may cause peripheral edema. Exercise caution when co-administering Pregabalin (Lyrica) and thiazolidinedione antidiabetic agents.


    Adverse reactions, side effects:

  • Most common adverse reactions (greater than or equal to 5% and twice placebo) in adults are dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, and thinking abnormal (primarily difficulty with concentration/attention).
  • Most common adverse reactions (greater than or equal to 5% and twice placebo) in pediatric patients for the treatment of partial-onset seizures are increased weight and increased appetite.
  • To report suspected adverse reactions of Lyrica (Pregabalin) pills contact Pfizer Inc. or your local FDA.


    Drug interactions:

    Since Pregabalin (Lyrica) is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (less than 2% of a dose recovered in urine as metabolites), and does not bind to plasma proteins, its pharmacokinetics are unlikely to be affected by other agents through metabolic interactions or protein binding displacement. In vitro and in vivo studies showed that Lyrica is unlikely to be involved in significant pharmacokinetic drug interactions. Specifically, there are no pharmacokinetic interactions between pregabalin and the following antiepileptic drugs: carbamazepine, valproic acid, lamotrigine, phenytoin, phenobarbital, and topiramate. Important pharmacokinetic interactions would also not be expected to occur between Lyrica and commonly used antiepileptic drugs.

    Pharmacodynamics

    Multiple oral doses of pregabalin were co-administered with oxycodone, lorazepam, or ethanol. Although no pharmacokinetic interactions were seen, additive effects on cognitive and gross motor functioning were seen when Lyrica was co-administered with these drugs. No clinically important effects on respiration were seen.


    Drug abuse and dependence:

    Controlled substance

    Pregabalin is a Schedule V controlled substance in the USA.

    Lyrica is not known to be active at receptor sites associated with drugs of abuse. As with any CNS active drug, carefully evaluate patients for history of drug abuse and observe them for signs of Lyrica (Pregabalin) misuse or abuse (e.g., development of tolerance, dose escalation, drug-seeking behavior).

    Abuse

    In a study of recreational users (N=15) of sedative/hypnotic drugs, including alcohol, Lyrica (450 mg, single dose) received subjective ratings of "good drug effect," "high" and "liking" to a degree that was similar to diazepam (30 mg, single dose). In controlled clinical studies in over 5500 patients, 4 % of Lyrica-treated patients and 1 % of placebo-treated patients overall reported euphoria as an adverse reaction, though in some patient populations studied, this reporting rate was higher and ranged from 1 to 12%.

    Dependence

    In clinical studies, following abrupt or rapid discontinuation of pregabalin, some patients reported symptoms including insomnia, nausea, headache or diarrhea, consistent with physical dependence. In the postmarketing experience, in addition to these reported symptoms there have also been reported cases of anxiety and hyperhidrosis.


    Use in specific populations:

  • Pregnancy: may cause fetal harm. Advise of potential risk to the fetus.
  • Lactation: breastfeeding is not recommended.


    • "We provided some exciting changes to the study plan within a couple of weeks of treatment dates and the team stepped up, as usual, and put a plan into place to give us the highest chance of success utilizing the criteria we requested."

    Manager Preclinical Research
    Large Medical Device Company

    Our expert preclinical Surgeons and Interventionalists can assist with human factors assessments and evaluating prototypes for your GLP or nonGLP preclinical studies.

    Preclinical Testing Solutions
    Throughout the
    Product Innovation Cycle.

    About Us

    Expertise

    Testing Services

    Customer Support

    Copyright © 2015 - 2024 Surpass, Inc. All Rights Reserved.